Ser684
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.8.0
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser684  -  ERK3 (human)

Site Information
IGIPQFHsPVGsPLk   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 13830500
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 13 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ) , mass spectrometry (in vitro) ( 13 ) , mutation of modification site ( 13 )
Disease tissue studied:
breast cancer ( 2 ) , lung cancer ( 3 , 4 , 5 , 6 , 10 ) , non-small cell lung cancer ( 3 , 4 , 5 , 7 , 8 , 10 ) , non-small cell lung adenocarcinoma ( 3 , 4 , 5 , 6 , 8 ) , non-small cell large cell lung carcinoma ( 4 ) , non-small cell squamous cell lung carcinoma ( 6 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 3 ) , Calu 6 (pulmonary) ( 10 ) , Calu-3 (pulmonary) ( 5 ) , H2009 (pulmonary) ( 10 ) , H2077 (pulmonary) ( 10 ) , H2887 (pulmonary) ( 10 ) , H322M (pulmonary) ( 10 ) , HCC1359 (pulmonary) ( 10 ) , HCC15 (pulmonary) ( 6 ) , HCC2279 (pulmonary) ( 10 ) , HCC4006 (pulmonary) ( 10 ) , HCC827 (pulmonary) ( 5 , 10 ) , HeLa (cervical) ( 1 , 13 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 2 ) , HMLER ('stem, breast cancer') ( 2 ) , Jurkat (T lymphocyte) ( 11 , 12 ) , K562 (erythroid) ( 9 ) , LCLC-103H (pulmonary) ( 10 ) , LOU-NH91 (squamous) ( 6 , 10 ) , lung ( 3 , 4 , 5 , 6 ) , NCI-H1299 (pulmonary) ( 4 ) , NCI-H1355 (pulmonary) ( 3 ) , NCI-H1568 (pulmonary) ( 10 ) , NCI-H1648 (pulmonary) ( 10 ) , NCI-H1650 (pulmonary) ( 5 ) , NCI-H1703 (squamous) ( 6 ) , NCI-H1734 (pulmonary) ( 4 ) , NCI-H1792 (pulmonary) ( 3 ) , NCI-H1944 (pulmonary) ( 4 ) , NCI-H1975 (pulmonary) ( 5 ) , NCI-H2073 (pulmonary) ( 6 ) , NCI-H2106 (pulmonary) ( 5 ) , NCI-H2172 (pulmonary) ( 10 ) , NCI-H2228 (pulmonary) ( 8 ) , NCI-H23 (pulmonary) ( 3 ) , NCI-H2342 (pulmonary) ( 6 ) , NCI-H3122 (pulmonary) ( 7 ) , NCI-H358 (pulmonary) ( 4 ) , NCI-H441 (pulmonary) ( 3 ) , NCI-H460 (pulmonary) ( 4 , 10 ) , NCI-H647 (pulmonary) ( 10 )

Upstream Regulation
Kinases, in vitro:
CDK1 (human) ( 13 )

Downstream Regulation
Effects of modification on ERK3:
protein stabilization ( 13 )

References 

1

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

2

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

7

Rikova K (2013) CST Curation Set: 18860; Year: 2012; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT
Curated Info

8

Rikova K (2013) CST Curation Set: 18859; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT
Curated Info

9

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

10

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

11

Guo A (2012) CST Curation Set: 13982; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

12

Mulhern D (2012) CST Curation Set: 13938; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

13

Tanguay PL, Rodier G, Meloche S (2010) C-terminal domain phosphorylation of ERK3 controlled by Cdk1 and Cdc14 regulates its stability in mitosis. Biochem J 428, 103-11
20236090   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.